Evidence supporting the use of: Spirulina
For the health condition: Tuberculosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Spirulina, a blue-green algae, has been investigated for its potential role in supporting the treatment of tuberculosis (TB). The interest in spirulina for TB primarily arises from its immunomodulatory, anti-inflammatory, and antioxidant properties. Several in vitro and animal studies have suggested that spirulina can stimulate immune responses, particularly by enhancing macrophage activity and increasing the production of cytokines such as interferon-gamma and interleukin-2, both of which are important in the body's defense against Mycobacterium tuberculosis, the causative agent of TB.

A small number of clinical studies have examined spirulina as an adjunct therapy in TB patients. For example, a randomized controlled trial in Egypt (2011) found that TB patients who received spirulina supplementation in addition to standard therapy showed improved nutritional status and some immune parameters compared to those on standard therapy alone. However, these studies are limited by small sample sizes, short duration, and methodological weaknesses. There is no substantial evidence that spirulina alone can treat or cure tuberculosis; rather, it may offer supportive benefits such as enhancing nutritional status or modulating immune function during standard anti-TB therapy.

In summary, while there is some preliminary scientific evidence suggesting that spirulina may be beneficial as an adjunct in TB treatment, the quality and quantity of evidence are still insufficient. Spirulina should not be used as a replacement for established TB therapies, and more rigorous clinical trials are needed to confirm its efficacy and safety in this context.

More about spirulina
More about Tuberculosis